Literature DB >> 28826176

Relative Incidence of Seizures and Myoclonus in Alzheimer's Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia.

Alexander J Beagle1, Sonja M Darwish1, Kamalini G Ranasinghe1, Alice L La1, Elissaios Karageorgiou1,2, Keith A Vossel1,3.   

Abstract

BACKGROUND: Patients with Alzheimer's disease (AD) are more prone to seizures and myoclonus, but relative risk of these symptoms among other dementia types is unknown.
OBJECTIVE: To determine incidence of seizures and myoclonus in the three most common neurodegenerative dementias: AD, dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD).
METHODS: Our institution's medical records were reviewed for new-onset unprovoked seizures and myoclonus in patients meeting criteria for AD (n = 1,320), DLB (n = 178), and FTD (n = 348). Cumulative probabilities of developing seizures and myoclonus were compared between diagnostic groups, whereas age-stratified incidence rates were determined relative to control populations.
RESULTS: The cumulative probability of developing seizures after disease onset was 11.5% overall, highest in AD (13.4%) and DLB (14.7%) and lowest in FTD (3.0%). The cumulative probability of developing myoclonus was 42.1% overall, highest in DLB (58.1%). The seizure incidence rates, relative to control populations, were nearly 10-fold in AD and DLB, and 6-fold in FTD. Relative seizure rates increased with earlier age-at-onset in AD (age <50, 127-fold; 50-69, 21-fold; 70+, 2-fold) and FTD (age <50, 53-fold; 50-69, 9-fold), and relative myoclonus rates increased with earlier age-at-onset in all groups. Seizures began an average of 3.9 years after the onset of cognitive or motor decline, and myoclonus began 5.4 years after onset.
CONCLUSIONS: Seizures and myoclonus occur with greater incidence in patients with AD, DLB, and FTD than in the general population, but rates vary with diagnosis, suggesting varied pathomechanisms of network hyperexcitability. Patients often experience these symptoms early in disease, suggesting hyperexcitability could be an important target for interventions.

Entities:  

Keywords:  Alzheimer’s disease; dementia with Lewy bodies; epilepsy; frontotemporal dementia

Mesh:

Year:  2017        PMID: 28826176      PMCID: PMC5608587          DOI: 10.3233/JAD-170031

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  57 in total

1.  Frontotemporal dementia progresses to death faster than Alzheimer disease.

Authors:  E D Roberson; J H Hesse; K D Rose; H Slama; J K Johnson; K Yaffe; M S Forman; C A Miller; J Q Trojanowski; J H Kramer; B L Miller
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

2.  rs5848 polymorphism and serum progranulin level.

Authors:  Ging-Yuek R Hsiung; Alice Fok; Howard H Feldman; Rosa Rademakers; Ian R A Mackenzie
Journal:  J Neurol Sci       Date:  2010-11-02       Impact factor: 3.181

3.  Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease.

Authors:  E D Louis; L A Klatka; Y Liu; S Fahn
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

Review 4.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

5.  Is the risk of developing Alzheimer's disease greater for women than for men?

Authors:  L E Hebert; P A Scherr; J J McCann; L A Beckett; D A Evans
Journal:  Am J Epidemiol       Date:  2001-01-15       Impact factor: 4.897

6.  The incidence and prevalence of myoclonus in Olmsted County, Minnesota.

Authors:  J N Caviness; L I Alving; D M Maraganore; R A Black; S K McDonnell; W A Rocca
Journal:  Mayo Clin Proc       Date:  1999-06       Impact factor: 7.616

7.  Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma: a register-based follow-up study.

Authors:  M M Breteler; R R de Groot; L K van Romunde; A Hofman
Journal:  Am J Epidemiol       Date:  1995-12-15       Impact factor: 4.897

8.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

9.  Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study.

Authors:  L Forsgren; G Bucht; S Eriksson; L Bergmark
Journal:  Epilepsia       Date:  1996-03       Impact factor: 5.864

10.  Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease.

Authors:  Alice D Lam; Gina Deck; Alica Goldman; Emad N Eskandar; Jeffrey Noebels; Andrew J Cole
Journal:  Nat Med       Date:  2017-05-01       Impact factor: 53.440

View more
  26 in total

1.  Treatment of Seizures in Older Patients with Dementia.

Authors:  Benjamin Cretin
Journal:  Drugs Aging       Date:  2020-12-14       Impact factor: 3.923

2.  Pathogenic Tau Impairs Axon Initial Segment Plasticity and Excitability Homeostasis.

Authors:  Peter Dongmin Sohn; Cindy Tzu-Ling Huang; Rui Yan; Li Fan; Tara E Tracy; Carolina M Camargo; Kelly M Montgomery; Taylor Arhar; Sue-Ann Mok; Rebecca Freilich; Justin Baik; Manni He; Shiaoching Gong; Erik D Roberson; Celeste M Karch; Jason E Gestwicki; Ke Xu; Kenneth S Kosik; Li Gan
Journal:  Neuron       Date:  2019-09-18       Impact factor: 17.173

3.  Bi-directional association between epilepsy and dementia: The Framingham Heart Study.

Authors:  Maria Stefanidou; Alexa S Beiser; Jayandra Jung Himali; Teng J Peng; Orrin Devinsky; Sudha Seshadri; Daniel Friedman
Journal:  Neurology       Date:  2020-10-23       Impact factor: 9.910

4.  Cognitive Effects of Montelukast: A Pharmaco-EEG Study.

Authors:  Fabian Schwimmbeck; Wolfgang Staffen; Christopher Höhn; Fabio Rossini; Nora Renz; Markus Lobendanz; Peter Reichenpfader; Bernhard Iglseder; Ludwig Aigner; Eugen Trinka; Yvonne Höller
Journal:  Brain Sci       Date:  2021-04-27

Review 5.  Epileptic Mechanisms Shared by Alzheimer's Disease: Viewed via the Unique Lens of Genetic Epilepsy.

Authors:  Jing-Qiong Kang
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 6.  Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models.

Authors:  Marina P Sánchez; Ana M García-Cabrero; Gentzane Sánchez-Elexpuru; Daniel F Burgos; José M Serratosa
Journal:  Int J Mol Sci       Date:  2018-04-05       Impact factor: 5.923

7.  Dementia in late-onset epilepsy: The Atherosclerosis Risk in Communities study.

Authors:  Emily L Johnson; Gregory L Krauss; Anna Kucharska-Newton; Marilyn S Albert; Jason Brandt; Keenan A Walker; Sevil Yasar; David S Knopman; Keith A Vossel; Rebecca F Gottesman
Journal:  Neurology       Date:  2020-10-23       Impact factor: 9.910

8.  ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids.

Authors:  Kathryn R Bowles; M Catarina Silva; Kristen Whitney; Taylor Bertucci; Joshua E Berlind; Jesse D Lai; Jacob C Garza; Nathan C Boles; Sidhartha Mahali; Kevin H Strang; Jacob A Marsh; Cynthia Chen; Derian A Pugh; Yiyuan Liu; Ronald E Gordon; Susan K Goderie; Rebecca Chowdhury; Steven Lotz; Keith Lane; John F Crary; Stephen J Haggarty; Celeste M Karch; Justin K Ichida; Alison M Goate; Sally Temple
Journal:  Cell       Date:  2021-07-26       Impact factor: 66.850

9.  Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor.

Authors:  Yasushi Yabuki; Jiaqi Liu; Ichiro Kawahata; Hisanao Izumi; Yasuharu Shinoda; Kohei Koga; Shinya Ueno; Norifumi Shioda; Kohji Fukunaga
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

10.  Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease.

Authors:  Tatyana Sarycheva; Heidi Taipale; Piia Lavikainen; Jari Tiihonen; Antti Tanskanen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.